Abstract
© 2012 The Authors. doi: 10.2340/00015555-1166 Journal Compilation © 2012 Acta Dermato-Venereologica. ISSN 0001-5555 Imiquimod (AldaraTM, 3M Pharmaceuticals) is a member of the imidazoquinolone family of drugs. It is a topical treatment approved by the US Food and Drug Administration (FDA) for the treatment of external genital and perianal warts, non-hypertrophic actinic keratoses in immunocompetent individuals, and superficial basal cell carcinoma (1). Numerous off-label indications have been reported. Lately, imiquimod has been proposed for the treatment of superficial pigmented lesions, such as melanoma in situ and lentigo maligna (LM) (2).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
